Antares Pharma, Inc. (ATRS): Price and Financial Metrics
ATRS Price/Volume Stats
|Current price||$5.59||52-week high||$5.60|
|Prev. close||$5.59||52-week low||$3.11|
|Day high||$5.60||Avg. volume||3,291,313|
|50-day MA||$4.86||Dividend yield||N/A|
|200-day MA||$3.91||Market Cap||955.06M|
ATRS Stock Price Chart Interactive Chart >
Antares Pharma, Inc. (ATRS) Company Bio
Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company was founded in 1979 and is based in Ewing, New Jersey.
Most Popular Stories View All
ATRS Latest News Stream
|Loading, please wait...|
ATRS Latest Social Stream
View Full ATRS Social Stream
Latest ATRS News From Around the Web
Below are the latest news stories about Antares Pharma Inc that investors may wish to consider to help them evaluate ATRS as an investment opportunity.
Antares Pharma (NASDAQ:ATRS) Could Easily Take On More Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating Results
EWING, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its fourth quarter and full-year 2021 financial and operating results on Thursday, March 3, 2022, before the market opens. Antares will host a conference call on Thursday, March 3, 2022 at 8:30am ET to discuss the results. The dial-in numbers are (888) 254-3590 for domestic callers and (323) 794-2551 for international callers. The
Henry Schein (HSIC) Q4 Earnings and Revenues Beat Estimates
Henry Schein (HSIC) delivered earnings and revenue surprises of 18.89% and 4.60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO®
PDUFA target action date set for March 28, 2022EWING, N.J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted its New Drug Application (“NDA”) resubmission for TLANDO® (testosterone undecanoate), an oral treatment for testosterone replacement therapy (“TRT”). The FDA designated the NDA as a Class 1 resubmission with a two-month review goal perio
Arrow Financial Corp Buys iShares Core MSCI International Developed Markets , PowerShares QQQ ...
Glens Falls, NY, based Investment company Arrow Financial Corp (Current Portfolio) buys iShares Core MSCI International Developed Markets , PowerShares QQQ Trust Ser 1, Caterpillar Inc, Dollar Tree Inc, Activision Blizzard Inc, sells Netflix Inc, iShares iBonds Dec 2021 Term Corporate ETF, Lockheed Martin Corp, Gilead Sciences Inc, Goldman Sachs Group Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Arrow Financial Corp.
ATRS Price Returns
Continue Researching ATRSWant to do more research on Antares Pharma Inc's stock and its price? Try the links below:
Antares Pharma Inc (ATRS) Stock Price | Nasdaq
Antares Pharma Inc (ATRS) Stock Quote, History and News - Yahoo Finance
Antares Pharma Inc (ATRS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...